A percentage needs a named measurement
A clinic may advertise tested or high purity beside a vial photograph. Before treating that as a complete quality assurance claim, ask what was tested, by whom, when and for which batch. A percentage without a named measurement leaves its meaning unresolved. A result for an ingredient is also different from a result for the finished preparation that will be dispensed.
Our practical rule is to keep the claim as narrow as the report. If a document identifies an assay result, describe that assay result. If it does not report another property, leave that property unknown. This approach is less dramatic than a pass or fail badge, but it is more useful when deciding what follow-up information you need from the provider or pharmacy.
Why sterile preparation needs particular attention
FDA warned compounders about using food-grade NAD+ ingredients to prepare intravenous products without appropriate processing. The agency described reports including chills, shaking, vomiting and fatigue, with some people requiring medical treatment, and noted consistency with excessive endotoxin exposure. [1] This is a concern about ingredient suitability and preparation quality; it should not be rewritten as a measured event rate for every NAD+ product.
For the buyer, a claim about the ingredient's purity therefore leaves important questions unanswered. Ask who prepares the sterile medicine, which facility and lot the report concerns, and which finished-product tests were performed. A provider should be able to explain the documents it uses in ordinary language. You should not have to infer the complete quality system from a graphic showing one large number.
Do not let a certificate answer an unasked question
A certificate can be technically detailed and still leave the consumer's central question unresolved. If your concern is the finished preparation, a document about raw material requires an explanation of what happened afterward. If your concern is an individual lot, a report from another lot has a different scope. If your concern is transport and storage, a release result does not itself describe every condition the product later encountered. State the question first, then decide whether the document is relevant to it.
This is also why units and acceptance criteria matter. A result without its method and reporting limit may be difficult to interpret outside the laboratory. Ask the issuer to explain terms such as below a limit rather than translating them yourself into absent under every circumstance. This article does not provide technical release specifications or authorize a reader to decide whether a preparation is fit to inject. It helps identify what a qualified pharmacy should clarify.
Compare that product-quality question with the limits of adverse-event evidence. A safety communication is not a batch certificate, and a batch certificate is not a clinical trial. The biomarker guide adds the clinical-outcome distinction, while the pharmacy framework guide explains why facility registration has its own meaning. Reading these sources together makes the boundary of each claim easier to see.
A provider comparison should therefore record the actual document available and any important missing connection. It should avoid implying that every order is independently tested merely because one example report is public. It should also avoid accusing another provider of a defect based solely on a missing public certificate. The unresolved question is what evidence supports the quality assurance claim for the preparation the patient will actually receive.
Clinical research cannot certify a retail batch
The 2019 NAD+ pharmacokinetic pilot involved 11 men: eight received NAD+ and three saline controls (n=11). The study measured plasma and urine metabolites during a six-hour infusion [2]. That small controlled experiment can inform a question about NAD+ handling under its protocol; it does not certify the identity, potency, sterility or endotoxin level of a different pharmacy’s finished preparation. Clinical study findings and product-quality documents should therefore be read as different evidence.
The useful lesson is about matching evidence to the actual product. If a clinic names a partner pharmacy, establish whether that is the facility responsible for your prescription. If it supplies a report, check that the identifying information matches the relevant item. An unrelated supplier's certificate cannot resolve questions about a different preparation, even when the product names look similar.
Make the document readable before comparing providers
A sensible document review starts with identity: sample description, batch identifier, date and laboratory. Then read the test name, method, units, acceptance criteria and actual result. If any of those fields is missing or unclear, ask the issuing laboratory or pharmacy to explain it. This article is a guide to questions, not a technical certification of any report.
Keep chain of custody in view too. Ask how the sample was selected and whether it represents the finished lot. A report can be authentic while having limited relevance to the item being offered. Avoid assuming that a public example posted months earlier establishes the quality of every later prescription. Record the exact claim and the unresolved question alongside the document.
Keep quality, effectiveness and cost separate
Even an informative quality report does not show that a treatment improves a clinical outcome. Evidence of benefit needs its own relevant human studies. Conversely, a study about a molecule does not certify the preparation supplied by a particular business. These questions need to be examined together without substituting one for another.
Read the NAD+ benefit review and the safety review alongside any provider documents. Use the shortlist builder to save questions about the compounder and testing, and the care cost planner to compare the separate financial commitment. A more expensive plan does not itself establish stronger evidence or better testing.
What a report can and cannot resolve
Imagine receiving a certificate that reports a high purity percentage for an ingredient. Before applying that result to a prescription, ask whether the tested sample was the raw ingredient or the finished injectable preparation. Then ask whether the batch identifier matches the dispensed medicine and whether the methods address the particular claim being made. A result on a different sample cannot by itself establish the properties of the vial in front of you.
FDA has specifically warned compounders about ingredients unsuitable for sterile preparation [1]. The relevant lesson is broader than any marketing adjective: identity and potency do not answer every contamination question. Sterility and endotoxin testing are different questions, and a claim that one was assessed should not be rewritten as proof that both were assessed. Likewise, a laboratory report is not an independent confirmation of every aspect of the clinical service.
Ask the dispensing pharmacy to explain an unclear report rather than trying to interpret an isolated percentage. Keep the product-quality question separate from the benefit question. Even a preparation with informative, relevant testing does not acquire evidence that NAD+ injections improve energy or aging. Those clinical claims require appropriate human outcome studies. A complete comparison should therefore preserve two uncertainties separately: what is known about the preparation, and what is known about the proposed treatment benefit.